DexCom (NASDAQ:DXCM) Director Mark Foletta Sells 2,000 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM) Director Mark Foletta sold 2,000 shares of the firm’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $80.00, for a total value of $160,000.00. Following the transaction, the director owned 50,852 shares in the company, valued at $4,068,160. The trade was a 3.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Trading Down 0.4%

Shares of NASDAQ DXCM opened at $86.94 on Wednesday. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $87.85. The firm has a market cap of $32.81 billion, a PE ratio of 34.36, a price-to-earnings-growth ratio of 1.48 and a beta of 1.41. The business has a fifty day simple moving average of $73.74 and a two-hundred day simple moving average of $69.43. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. The business had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The business’s revenue was up 13.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.48 EPS. Analysts expect that DexCom, Inc. will post 2.64 earnings per share for the current fiscal year.

Institutional Trading of DexCom

A number of institutional investors have recently modified their holdings of the company. MassMutual Private Wealth & Trust FSB raised its stake in shares of DexCom by 15.4% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 1,147 shares of the medical device company’s stock worth $77,000 after acquiring an additional 153 shares in the last quarter. V Square Quantitative Management LLC boosted its stake in DexCom by 1.8% in the first quarter. V Square Quantitative Management LLC now owns 9,618 shares of the medical device company’s stock valued at $604,000 after acquiring an additional 172 shares in the last quarter. Essex Financial Services Inc. grew its holdings in DexCom by 5.7% in the first quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company’s stock worth $204,000 after purchasing an additional 175 shares during the last quarter. Keel Point LLC grew its holdings in DexCom by 3.1% in the fourth quarter. Keel Point LLC now owns 6,473 shares of the medical device company’s stock worth $430,000 after purchasing an additional 193 shares during the last quarter. Finally, Integrated Wealth Concepts LLC increased its position in shares of DexCom by 6.3% during the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after purchasing an additional 196 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

Trending Headlines about DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Argus raised its price target to $96 from $86 and maintained a “buy” rating, implying approximately 10% potential upside from the referenced price. Benzinga
• Positive Sentiment: DexCom’s latest quarterly results exceeded expectations, with adjusted earnings of $0.70 per share versus a $0.61 consensus estimate and revenue of $1.31 billion versus $1.29 billion expected. Revenue increased 13.1% year over year, while operating income reportedly grew 49.7%; management also raised its fiscal-year 2026 guidance. DexCom: Still A Cautious Buy Following Earnings
• Positive Sentiment: Growth catalysts include adoption of the G7 glucose-monitoring system, international expansion and the “Road to 100” initiative aimed at broadening diabetes coverage. Margin improvement, share repurchases and a solid balance sheet further support the investment case. DexCom: Still A Cautious Buy Following Earnings
• Positive Sentiment: Technical momentum has improved: DXCM moved above its 20-day moving average and reached a new 52-week high, signaling continued short-term buying interest. DexCom 52-Week High
• Neutral Sentiment: Analyst opinion remains broadly constructive, with another reported price-target increase to $82; however, targets vary significantly. At roughly 34 times earnings, valuation leaves the stock sensitive to any slowdown in growth or weaker guidance. DexCom Price Target Raised
• Negative Sentiment: Director Mark G. Foletta sold a combined 4,000 shares for approximately $330,640 under a pre-arranged Rule 10b5-1 plan. Because the sales were scheduled in advance and he retains a substantial position, the transactions are a limited negative signal rather than clear evidence of declining confidence. SEC Insider Trading Filing

Analyst Upgrades and Downgrades

Several research analysts have issued reports on DXCM shares. JPMorgan Chase & Co. increased their target price on shares of DexCom from $65.00 to $82.00 and gave the stock a “neutral” rating in a report on Friday, July 31st. Piper Sandler reaffirmed an “overweight” rating and issued a $95.00 price target (up from $88.00) on shares of DexCom in a research report on Friday. William Blair upgraded shares of DexCom to a “strong-buy” rating in a research note on Friday, May 15th. Sanford C. Bernstein set a $77.00 price objective on shares of DexCom in a report on Friday, May 1st. Finally, Mizuho boosted their price objective on shares of DexCom from $90.00 to $95.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $88.71.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.